As REPO-TRIAL is nearing conclusion, the entire team is currently convening in Madrid for its final General Assembly (GA) Meeting. This closing meeting is the occasion to evaluate results from two ongoing Phase IIa clinical trials, REPO-STROKE II and REPO-HFpEF II. Based on new insights into systems medicine gained at the University of Maastricht, a bioinformatics team distributed between Syddansk Universitiy (Kopenhagen), the Technical University of Munich and Hamburg University in Germany, as well as Newcastle University (United Kingdom) collaborated to design triple combinations of approved drugs that block critical pathways in conditions with significant unmet medical need.
